**Supplementary Table 1.** Patient disposition by dose level and diagnosis (safety population).†

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Cohort 1** | **Cohort 2** | **Overall (N = 33)** |
| **Dose level, mg/day** | **AML(n = 21)** | **MDS(n = 4)** | **All(n = 25)** | **CLL(n = 4)** | **MCL(n = 4)** | **All(n = 8)** |
| 0.10 | 3 (14.3) | 0 (0.0) | 3 (12.0) | 1 (25.0) | 2 (50.0) | 3 (37.5) | 6 (18.2) |
| 0.20 | 2 (9.5) | 1 (25.0) | 3 (12.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (9.1) |
| 0.30 | 3 (14.3) | 2 (50.0) | 5 (20.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (15.2) |
| 0.45 | 3 (14.3) | 0 (0.0) | 3 (12.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (9.1) |
| 0.90 | 4 (19.0) | 0 (0.0) | 4 (16.0) | 3 (75.0) | 2 (50.0) | 5 (62.5) | 9 (27.3) |
| 1.35 | 3 (14.3) | 0 (0.0) | 3 (12.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (9.1) |
| 2.00 | 3 (14.3) | 1 (25.0) | 4 (16.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (12.1) |

†Data presented as n (%).

AML: acute myeloid leukemia; CLL: chronic lymphocytic leukemia; MCL: mantle cell lymphoma;
MDS: myelodysplastic syndrome.